An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease

ConclusionsAclidinium/formoterol 400/12 µg twice daily was well-tolerated in patients from China with moderate-to-severe COPD. Safety findings were consistent with the known safety profile.Clinical Trial IdentifierClinicalTrials.gov, NCT03276078.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research